CA2998528A1 - Modified cytotoxins and their therapeutic use - Google Patents

Modified cytotoxins and their therapeutic use Download PDF

Info

Publication number
CA2998528A1
CA2998528A1 CA2998528A CA2998528A CA2998528A1 CA 2998528 A1 CA2998528 A1 CA 2998528A1 CA 2998528 A CA2998528 A CA 2998528A CA 2998528 A CA2998528 A CA 2998528A CA 2998528 A1 CA2998528 A1 CA 2998528A1
Authority
CA
Canada
Prior art keywords
moiety
compound
protein
pharmaceutical composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2998528A
Other languages
English (en)
French (fr)
Inventor
Cassandra E. CALLMANN
Matthew P. THOMPSON
Clare L. M. LEGUYADER
Nathan C. Gianneschi
Paul A. Bertin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vybyl Holdings Inc
University of California San Diego UCSD
Original Assignee
Vybyl Holdings Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vybyl Holdings Inc, University of California San Diego UCSD filed Critical Vybyl Holdings Inc
Publication of CA2998528A1 publication Critical patent/CA2998528A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CA2998528A 2015-09-22 2016-09-21 Modified cytotoxins and their therapeutic use Abandoned CA2998528A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222059P 2015-09-22 2015-09-22
US62/222,059 2015-09-22
PCT/US2016/052829 WO2017053391A1 (en) 2015-09-22 2016-09-21 Modified cytotoxins and their therapeutic use

Publications (1)

Publication Number Publication Date
CA2998528A1 true CA2998528A1 (en) 2017-03-30

Family

ID=58276138

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998528A Abandoned CA2998528A1 (en) 2015-09-22 2016-09-21 Modified cytotoxins and their therapeutic use

Country Status (14)

Country Link
US (3) US10023581B2 (https=)
EP (1) EP3353159A4 (https=)
JP (1) JP2018527360A (https=)
KR (1) KR20180045001A (https=)
CN (1) CN108368075A (https=)
AU (1) AU2016326392B2 (https=)
CA (1) CA2998528A1 (https=)
HK (1) HK1254461A1 (https=)
IL (1) IL257932A (https=)
MX (1) MX380314B (https=)
MY (1) MY193776A (https=)
RU (1) RU2721949C2 (https=)
WO (1) WO2017053391A1 (https=)
ZA (1) ZA201801482B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998528A1 (en) * 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2018237139A1 (en) * 2017-03-22 2019-10-17 The Regents Of The University Of California Modified oligonucleotides and therapeutic uses thereof
WO2021007322A1 (en) * 2019-07-09 2021-01-14 Northwestern University Methods of using modified cytotoxins to treat cancer
IT202100025172A1 (it) 2021-09-30 2023-03-30 Indena Spa Processo per la preparazione di derivati tassanici
KR20250057244A (ko) 2023-10-20 2025-04-29 (주)블루엔씨 고정밀 3d 프린팅 기반 금형 제작 방법 및 장치

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
AU6803494A (en) * 1993-06-07 1995-01-03 British Technology Group Limited Anticancer compounds
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
AU735205B2 (en) 1997-05-16 2001-07-05 Commonwealth Scientific And Industrial Research Organisation Vaccine and assay
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
NO319551B1 (no) 2003-07-04 2005-08-29 Thia Medica As Proteinmateriale fra enkeltceller
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP1804838A2 (en) * 2004-09-15 2007-07-11 Drug Discovery Laboratory AS Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TW200731991A (en) * 2005-12-20 2007-09-01 Sonus Pharma Inc Lipophilic di(anticancer drug) compounds, compositions and related methods
KR20100126361A (ko) 2008-02-08 2010-12-01 에일러론 테라퓨틱스 인코포레이티드 치료용 펩티드유사 거대고리
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
WO2010107487A2 (en) 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
EP2413937A1 (en) 2009-04-02 2012-02-08 Shire LLC Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
WO2011085000A2 (en) 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2536434B1 (en) 2010-02-16 2016-04-20 Novo Nordisk A/S Purification method
RU2012151134A (ru) * 2010-05-10 2014-06-20 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Логометрическая комбинаторная доставка лекарственных средств
EP2392324A1 (en) * 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
WO2012048204A2 (en) * 2010-10-08 2012-04-12 Virginia Commonwealth University Prodrugs utilizing a transporter directed uptake mechanism
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
KR101435261B1 (ko) 2012-07-23 2014-09-02 아주대학교산학협력단 항암제-링커-알부민 결합체, 이의 제조방법 및 상기 결합체를 포함하는 약물 전달용 조성물
EP2922817A4 (en) * 2012-11-21 2016-06-22 Univ Sydney OMEGA-3 Analogs
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
US20160115192A1 (en) * 2013-06-10 2016-04-28 Cedars-Sinai Medical Center Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
CN104478813A (zh) * 2014-12-20 2015-04-01 苏州博源医疗科技有限公司 5-氟尿嘧啶衍生物、5-氟尿嘧啶免疫原及其抗体与5-氟尿嘧啶检测试剂盒
CA2998528A1 (en) * 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) * 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US20200048198A1 (en) * 2017-03-22 2020-02-13 The Regents Of The University Of California Modified histone deacetylase inhibitors and uses thereof
WO2018175622A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified anthracycline compounds and their therapeutic use
WO2018175601A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified platinum compounds and therapeutic uses thereof
US20200046859A1 (en) * 2017-04-27 2020-02-13 The Regents Of The University Of California Modified mri contrast agents and uses thereof

Also Published As

Publication number Publication date
ZA201801482B (en) 2021-07-28
MX2018002514A (es) 2018-08-15
AU2016326392A1 (en) 2018-03-22
HK1254461A1 (zh) 2019-07-19
RU2721949C2 (ru) 2020-05-25
US10023581B2 (en) 2018-07-17
JP2018527360A (ja) 2018-09-20
MX380314B (es) 2025-03-12
EP3353159A1 (en) 2018-08-01
US10654864B2 (en) 2020-05-19
MY193776A (en) 2022-10-27
RU2018107843A3 (https=) 2019-11-28
WO2017053391A1 (en) 2017-03-30
US20180222915A1 (en) 2018-08-09
US20210047338A1 (en) 2021-02-18
US20170080094A1 (en) 2017-03-23
KR20180045001A (ko) 2018-05-03
AU2016326392B2 (en) 2021-02-11
IL257932A (en) 2018-06-03
CN108368075A (zh) 2018-08-03
EP3353159A4 (en) 2019-03-27
RU2018107843A (ru) 2019-10-25

Similar Documents

Publication Publication Date Title
US10654864B2 (en) Modified cytotoxins and their therapeutic use
US20230302144A1 (en) Porphyrin Compounds and Compositions Useful for Treating Cancer
US20190381179A1 (en) Modified cytotoxins and their therapeutic use
US20210137957A1 (en) Modified anthracycline compounds and their therapeutic use
EP3378495B1 (en) Composition comprising novel glutamic acid derivative and block copolymer, and use thereof
US20220273607A1 (en) Methods of using modified cytotoxins to treat cancer
WO2018175595A1 (en) Modified histone deacetylase inhibitors and uses thereof
WO2018175589A1 (en) Modified peptides and uses thereof for treating cancer
WO2018175601A1 (en) Modified platinum compounds and therapeutic uses thereof
CN115260107B (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
AU2018258345A1 (en) Modified mri contrast agents and uses thereof
HK40008068B (zh) 用於治疗癌症的卟啉化合物和组合物
CN102649810A (zh) 喜树碱衍生物、其制备方法和用途
KR20200053158A (ko) 약물-결합 화합물 및 이의 용도
HK40019846A (en) Modified mri contrast agents and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210830

FZDE Discontinued

Effective date: 20230321